by Kyle Doherty
A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2
In the statement, the ASCO panel recommended that the FDA … Read more
by Jax DiEugenio
Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more
by IPM staff
A new study from the Mayo Clinic finds that current screening protocols fail to catch a significant number of individuals with genetic mutations linked to hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, which increase … Read more
by Linda Wang
Physical activity can have many benefits for cancer survivors, from improving their quality of life to potentially making it less likely that their disease will come back. Yet studies have shown that many cancer survivors struggle to … Read more
—No difference in adverse events, clinical benefit, OS for patients with or without waivers
by Charles Bankhead
Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large retrospective review showed.
Patients who received waivers had a clinical benefit rate … Read more
Clearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
Clearity’s Perspective: This article highlights that some people with ovarian cancer who live in certain geographic locations, like rural areas, may get treated at centers with less experience treating ovarian cancer and/or fewer resources to support whole-person needs. Clearity offers … Read more
Led by Dr Melissa Merritt and Dr Nicola Meagher from the Daffodil Centre … Read more
by Edward Winstead
This story has an accompanying Q&A with Dr. Gwendolyn Quinn, Ph.D., of the New York University Perlmutter Cancer Center, on some of the challenges faced by LGBTQ+ people with cancer and ways to address them.
After surgery … Read more
by Sabrina Serani
The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.
While the FDA notes … Read more
By Josh Friedman
Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving … Read more
By Erin T. Welsh, MA
Asian, Black and Hispanic women with … Read more
By Mary Caffrey
Delayed diagnoses. Symptoms that are dismissed or misinterpreted. Feelings of anxiety because no one can offer a clear explanation for their condition.
These are just some of the experiences of women who have low-grade serous ovarian cancer … Read more
Researchers examined risks for Black and white women with endometriosis and fibroids to understand how common medical interventions for those conditions modified the outcomes
SEATTLE, WA — May 4, 2023 — A new Fred Hutchinson Cancer Center study in the
Clearity’s Perspective: Ask your health care team if they have a social worker, financial navigator, patient navigator, or nurse navigator who can help you manage the financial impacts of cancer. See Clearity’s Information and Support Resources for national organizations that … Read more
by Jennifer Southall
Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.
The findings, presented at American Association … Read more
by Matthew Shinkle
One of every four patients with a gynecologic oncology office visit had inadequate levels of cancer health literacy, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers found racial and ethnic … Read more
Ovarian cancer outcomes are less positive for Black and African American persons compared to other communities, but the reasons why are not entirely clear. Anne Mette Buhl, PhD, Director of Science and Clinical Trials, from The Clearity Foundation, recently contributed … Read more
by Kalie VanDewater
Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.
“Although trial results inform policies … Read more
by Nicolas Wrigley
Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.… Read more
